Literature DB >> 32734650

Metabolic perturbations prior to hepatocellular carcinoma diagnosis: Findings from a prospective observational cohort study.

Magdalena Stepien1, Pekka Keski-Rahkonen1, Agneta Kiss1, Nivonirina Robinot1, Talita Duarte-Salles1,2, Neil Murphy1, Gabriel Perlemuter3,4,5, Vivian Viallon1, Anne Tjønneland6, Agnetha Linn Rostgaard-Hansen6, Christina C Dahm7, Kim Overvad7,8, Marie-Christine Boutron-Ruault9,10, Francesca Romana Mancini9,10, Yahya Mahamat-Saleh9,10, Krasimira Aleksandrova11, Rudolf Kaaks12, Tilman Kühn12, Antonia Trichopoulou13,14, Anna Karakatsani13,15, Salvatore Panico16, Rosario Tumino17, Domenico Palli18, Giovanna Tagliabue19, Alessio Naccarati20, Roel C H Vermeulen21, Hendrik Bastiaan Bueno-de-Mesquita22,23,24,25, Elisabete Weiderpass1, Guri Skeie26, Jose Ramón Quirós27, Eva Ardanaz28,29,30, Olatz Mokoroa30,31, Núria Sala32, Maria-Jose Sánchez30,33, José María Huerta30,34, Anna Winkvist35,36, Sophia Harlid37, Bodil Ohlsson38, Klas Sjöberg39, Julie A Schmidt40, Nick Wareham41, Kay-Tee Khaw42, Pietro Ferrari1, Joseph A Rothwell1,10, Marc Gunter1, Elio Riboli24, Augustin Scalbert1, Mazda Jenab1.   

Abstract

Hepatocellular carcinoma (HCC) development entails changes in liver metabolism. Current knowledge on metabolic perturbations in HCC is derived mostly from case-control designs, with sparse information from prospective cohorts. Our objective was to apply comprehensive metabolite profiling to detect metabolites whose serum concentrations are associated with HCC development, using biological samples from within the prospective European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (>520 000 participants), where we identified 129 HCC cases matched 1:1 to controls. We conducted high-resolution untargeted liquid chromatography-mass spectrometry-based metabolomics on serum samples collected at recruitment prior to cancer diagnosis. Multivariable conditional logistic regression was applied controlling for dietary habits, alcohol consumption, smoking, body size, hepatitis infection and liver dysfunction. Corrections for multiple comparisons were applied. Of 9206 molecular features detected, 220 discriminated HCC cases from controls. Detailed feature annotation revealed 92 metabolites associated with HCC risk, of which 14 were unambiguously identified using pure reference standards. Positive HCC-risk associations were observed for N1-acetylspermidine, isatin, p-hydroxyphenyllactic acid, tyrosine, sphingosine, l,l-cyclo(leucylprolyl), glycochenodeoxycholic acid, glycocholic acid and 7-methylguanine. Inverse risk associations were observed for retinol, dehydroepiandrosterone sulfate, glycerophosphocholine, γ-carboxyethyl hydroxychroman and creatine. Discernible differences for these metabolites were observed between cases and controls up to 10 years prior to diagnosis. Our observations highlight the diversity of metabolic perturbations involved in HCC development and replicate previous observations (metabolism of bile acids, amino acids and phospholipids) made in Asian and Scandinavian populations. These findings emphasize the role of metabolic pathways associated with steroid metabolism and immunity and specific dietary and environmental exposures in HCC development.
© 2020 UICC.

Entities:  

Keywords:  hepatocellular carcinoma; prospective observational cohort; untargeted metabolomics

Mesh:

Substances:

Year:  2020        PMID: 32734650     DOI: 10.1002/ijc.33236

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Metabolic signatures of hepatolithiasis using ultra-high performance liquid chromatography-tandem mass spectrometry.

Authors:  Cong Wang; Jun Yang; Enliang Li; Shuaiwu Luo; Chi Sun; Yuting Liao; Min Li; Jin Ge; Jun Lei; Fan Zhou; Linquan Wu; Wenjun Liao
Journal:  Metabolomics       Date:  2022-08-17       Impact factor: 4.747

2.  Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition.

Authors:  Marie Breeur; Pietro Ferrari; Laure Dossus; Mazda Jenab; Mattias Johansson; Sabina Rinaldi; Ruth C Travis; Mathilde His; Tim J Key; Julie A Schmidt; Kim Overvad; Anne Tjønneland; Cecilie Kyrø; Joseph A Rothwell; Nasser Laouali; Gianluca Severi; Rudolf Kaaks; Verena Katzke; Matthias B Schulze; Fabian Eichelmann; Domenico Palli; Sara Grioni; Salvatore Panico; Rosario Tumino; Carlotta Sacerdote; Bas Bueno-de-Mesquita; Karina Standahl Olsen; Torkjel Manning Sandanger; Therese Haugdahl Nøst; J Ramón Quirós; Catalina Bonet; Miguel Rodríguez Barranco; María-Dolores Chirlaque; Eva Ardanaz; Malte Sandsveden; Jonas Manjer; Linda Vidman; Matilda Rentoft; David Muller; Kostas Tsilidis; Alicia K Heath; Hector Keun; Jerzy Adamski; Pekka Keski-Rahkonen; Augustin Scalbert; Marc J Gunter; Vivian Viallon
Journal:  BMC Med       Date:  2022-10-19       Impact factor: 11.150

3.  Novel Biomarkers of Habitual Alcohol Intake and Associations With Risk of Pancreatic and Liver Cancers and Liver Disease Mortality.

Authors:  Erikka Loftfield; Magdalena Stepien; Vivian Viallon; Laura Trijsburg; Joseph A Rothwell; Nivonirina Robinot; Carine Biessy; Ingvar A Bergdahl; Stina Bodén; Matthias B Schulze; Manuela Bergman; Elisabete Weiderpass; Julie A Schmidt; Raul Zamora-Ros; Therese H Nøst; Torkjel M Sandanger; Emily Sonestedt; Bodil Ohlsson; Verena Katzke; Rudolf Kaaks; Fulvio Ricceri; Anne Tjønneland; Christina C Dahm; Maria-Jose Sánchez; Antonia Trichopoulou; Rosario Tumino; María-Dolores Chirlaque; Giovanna Masala; Eva Ardanaz; Roel Vermeulen; Paul Brennan; Demetrius Albanes; Stephanie J Weinstein; Augustin Scalbert; Neal D Freedman; Marc J Gunter; Mazda Jenab; Rashmi Sinha; Pekka Keski-Rahkonen; Pietro Ferrari
Journal:  J Natl Cancer Inst       Date:  2021-11-02       Impact factor: 13.506

Review 4.  Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk.

Authors:  Naoto Kubota; Naoto Fujiwara; Yujin Hoshida
Journal:  J Clin Med       Date:  2020-11-26       Impact factor: 4.241

5.  Metabolic Profiling Identified a Novel Biomarker Panel for Metabolic Syndrome-Positive Hepatocellular Cancer.

Authors:  Lin-Lin Cao; Yi Han; Yuanxiao Wang; Lin Pei; Zhihong Yue; Li Qin; Boyu Liu; Jingwen Cui; Mei Jia; Hui Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-26       Impact factor: 5.555

6.  A Serum Metabolite Classifier for the Early Detection of Type 2 Diabetes Mellitus-Positive Hepatocellular Cancer.

Authors:  Lin-Lin Cao; Yi Han; Lin Pei; Zhi-Hong Yue; Bo-Yu Liu; Jing-Wen Cui; Mei Jia; Hui Wang
Journal:  Metabolites       Date:  2022-07-01

7.  Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis.

Authors:  Jessica I Sanchez; Jingjing Jiao; Suet-Ying Kwan; Lucas Veillon; Marc O Warmoes; Lin Tan; Mobolaji Odewole; Nicole E Rich; Peng Wei; Philip L Lorenzi; Amit G Singal; Laura Beretta
Journal:  Cancer Prev Res (Phila)       Date:  2021-07-12

Review 8.  Biomarkers for hepatocellular carcinoma based on body fluids and feces.

Authors:  Ming-Cheng Guan; Wei Ouyang; Ming-Da Wang; Lei Liang; Na Li; Ting-Ting Fu; Feng Shen; Wan-Yee Lau; Qiu-Ran Xu; Dong-Sheng Huang; Hong Zhu; Tian Yang
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

9.  Knockout of Putative Tumor Suppressor Aldh1l1 in Mice Reprograms Metabolism to Accelerate Growth of Tumors in a Diethylnitrosamine (DEN) Model of Liver Carcinogenesis.

Authors:  Natalia I Krupenko; Jaspreet Sharma; Halle M Fogle; Peter Pediaditakis; Kyle C Strickland; Xiuxia Du; Kristi L Helke; Susan Sumner; Sergey A Krupenko
Journal:  Cancers (Basel)       Date:  2021-06-28       Impact factor: 6.575

10.  Data Processing Thresholds for Abundance and Sparsity and Missed Biological Insights in an Untargeted Chemical Analysis of Blood Specimens for Exposomics.

Authors:  Dinesh Kumar Barupal; Sadjad Fakouri Baygi; Robert O Wright; Manish Arora
Journal:  Front Public Health       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.